Skip to content
OpenCapital
Get started

CorMedix CRMD Other research and development — Total research and development

Other segment segments

Employee and contracted employee expense
$2.34M+113%

Similar metrics at other companies

Shattuck Labs, Inc. logo
STTKOther Research And Development — R&D
$4.67M+1.3%
Tyra Biosciences, Inc. logo
TYRAOther Development Programs — Research And Development Expense
$849K+65.2%
Arcutis Biotherapeutics, Inc. logo
ARQTOther program costs — R&D
$95K-92.0%
Zymeworks logo
ZYMEExpense for other preclinical and research programs — R&D
$7.26M+19.6%
Solid Biosciences Inc. logo
SLDBExternal Research And Development Other — Other Research And Development Expense
$2.86M+3.1%
EyePoint, Inc. logo
EYPTOther Direct Research And Development Expense
$759K+14.3%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's other research and development — total research and development.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's other research and development — total research and development?
CorMedix (CRMD) reported other research and development — total research and development of $4.87M in Q1 2026.
How has CorMedix's other research and development — total research and development changed year-over-year?
CorMedix's other research and development — total research and development increased by 132.9% year-over-year, from $2.09M to $4.87M.
What is the long-term trend for CorMedix's other research and development — total research and development?
Over 2 years (2023 to 2025), CorMedix's other research and development — total research and development has grown at a 39.6% compound annual growth rate (CAGR), from $5.94M to $11.58M.
What does other research and development — total research and development mean?
This metric represents the portion of total research and development expenditures allocated to secondary or exploratory pipeline projects outside of the company's primary lead product candidates. It reflects the firm's investment in long-term innovation, early-stage discovery, or non-core therapeutic programs. Monitoring this allocation helps investors assess the company's commitment to diversifying its clinical portfolio beyond its flagship commercial assets.